Discover ongoing clinical trials that may further our pipeline.
Motixafortide (BL-8040)
Investigator-initiated Phase 2 Study with combination chemotherapy (Gemcitabine and Nab-Paclitaxel), BL-8040, and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma
Metastatic pancreatic cancer
BL-8040 + Cemiplimab
(Libtayo) + Chemo
Investigator-initiated Motixafortide and Natalizumab in Sickle Cell Disease (SCD)
Sickle cell disease
Investigator-initiated Phase 1b, open-label study designed to evaluate the safety of BL-8040 (a CXCR4 antagonist) in patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections
ARDS secondary to COVID-19 and other respiratory viral infections
BL-8040